The MONARCH plus trial, primarily conducted in the Chinese population with HR + /HER2- advanced breast cancer, randomized patients to receive anastrozole/letrozole, fulvestrant plus abemaciclib, or a placebo. This evidence concerns the gene ERBB2 and breast carcinoma.